Join the Newsletter
SEARCH
Loading
Search Filters
  • Speakers
  • Audience
  • Topic
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
15:00
  1. Spotlight: A new lentiviral vector for in vivo CAR-T with high specificity and efficacy for multi-immune cell targeting
    Theatre 1 (Zafir)
    15 mins
    • Cell & Gene Therapy Clinical Pathways
     
    Stefanos Theoharis
    Stefanos Theoharis, CEO - OneChain Immunotherapeutics
15:05
  1. Presentation: A novel manufacturing platform for making any cell therapy a tumour targeted cell therapy.
    Workshop Room (Rossini 1&2)
    10 mins
    • Innovation Zone
     
    David Coe
    David Coe, CEO - CoED Biosciences
15:15
  1. Panel: The in vivo inflection: From breakthrough to clinical momentum, how far and how fast can this wave go?
    Theatre 1 (Zafir)
    45 mins
    • Cell & Gene Therapy Clinical Pathways
    The inflection is measurable: What recent in vivo clinical readouts are showing about delivery efficiency, expression control and safety—and where performance is becoming reproducible rather than exce ...
    Andrew Frazer
    Andrew Frazer, Associate Director, Scientific Solutions - Rose BioSolutions
    Margot Pont
    Margot Pont, VP Translational Development - Integra Therapeutics
    Maria Eugenia Alonso Ferrero
    Maria Eugenia Alonso Ferrero, Immunogenecity Science Director - Alexion Pharmaceuticals
    Stefanos Theoharis
    Stefanos Theoharis, CEO - OneChain Immunotherapeutics
  2. Panel: From scaled to standard of care: commercialising CGTs across Europe’s fragmented health systems
    Theatre 2 (Rubi)
    45 mins
    • Operational & Commercial Performance
     
    Angela Borghouts de Ruijter
    Angela Borghouts de Ruijter, Associate Director Market Access - Gilead
    Esteve Trias
    Esteve Trias, ATMP Expert
    Francis Pang
    Francis Pang, Senior Vice President, Global Market Access and International Geographic Expansion - Orchard Therapeutics
    Tamara Loos
    Tamara Loos, Consultant - ENIMAXE
16:00
  1. Break
    Exhibition Hall
    30 mins
    • Networking Break
     
16:30
  1. Roundtable: From Investment to Impact: The social return on novel therapies
    60 mins
    • Roundtable
    Angela Borghouts de Ruijter
    Angela Borghouts de Ruijter, Associate Director Market Access - Gilead
  2. Roundtable: From bench to build: How academic scientists turn ideas into fundable biotechs
    60 mins
    • Roundtable
    Laura Koivusalo
    Laura Koivusalo, CEO - StemSight
  3. Roundtable: Choosing Your Modality Early and Living With It: How platform, delivery and indication choices shape timelines, capital needs and exit options
    60 mins
    • Roundtable
    Carolina Pola
    Carolina Pola, CEO - STAb Therapeutics
  4. Roundtable: Creating visibility across the patient cell journey: Building customer engagement into CAR-T operations
    60 mins
    • Roundtable
    Danny Evans
    Danny Evans, Customer experience & commercial operations expert, Advanced Therapies - Lima Lime Consulting
  5. Roundtable: Cracking the EU Code: Turning regulatory & supply complexities into a smooth process
    60 mins
    • Roundtable
    Cristina Salado
    Cristina Salado, Assistant Professor - Universitat Pompeu Fabra
  6. Roundtable: Data that unlocks capital: What investors actually want to see at seed and Series A and what doesn’t move the needle
    60 mins
    • Roundtable
    Raphael Ognar
    Raphael Ognar, Co-founder - NKILT Therapeutics
  7. Roundtable: From great science to great business: Translating innovation into investment, commercialization and exit
    60 mins
    • Roundtable
    Mayra Battilani Becegato
    Mayra Battilani Becegato, Founder - AltrionBio
  8. Roundtable: Managing immunogenicity risk across the next generation of advanced therapies
    60 mins
    • Roundtable
    Maria Eugenia Alonso Ferrero
    Maria Eugenia Alonso Ferrero, Immunogenecity Science Director - Alexion Pharmaceuticals
  9. Roundtable: Moving biology across borders: Import/export, customs, chain-of-custody and compliance - What still trips teams up in 2026
    60 mins
    • Roundtable
    Lynette James
    Lynette James, VP Supply Chain & External Manufacturing - Quell Therapeutics
  10. Roundtable: Where impact meets returns: Rethinking how biotechs are built and funded
    60 mins
    • Roundtable
    Gonzalo Fernandez-Miranda
    Gonzalo Fernandez-Miranda, Co-founder & CEO - CureAge Therapeutics
17:30
  1. Drinks Reception
    Exhibition Hall
    105 mins
    • Networking Break
     
18:00
  1. CellBri Barcelona Demo Lab Tour
    InterContinental Hotel
    120 mins
    • Operational & Commercial Performance
    CellBri will be hosting an exclusive visit to our new demonstration facility at Cosymbio in Barcelona. Join us for an exclusive tour of our new demonstration lab at Cosymbio in Barcelona on September ...
09:00
  1. Innovation Exchange
    Theatre 1 (Zafir)
    90 mins
    • Plenary
    Join us for an exciting session where innovative biotech start-ups pitch their groundbreaking ideas and solutions. Watch as they present to a panel of expert investors, who will provide real-time feed ...
    Gadareth Higgs
    Gadareth Higgs, Partner - Advantary Capital Partners
    Malgorzata Rogalska
    Malgorzata Rogalska, Analyst - Ysios Capital
    Matt Symes
    Matt Symes, Investor - Delin Ventures
    Rahul Khetan
    Rahul Khetan, Venture Associate - UCB Ventures
10:30
  1. Panel: Designing CGTs in the age of agentic AI: How AI is transforming discovery and development
    Theatre 1 (Zafir)
    45 mins
    • Plenary
    From optional to inevitable: Where agentic and analytical AI are already changing discovery and early CGT development and what must be true for AI to become a trusted, default tool rather than a pilot ...
    Aneta Tyszkiewicz
    Aneta Tyszkiewicz, Director Data Digital - EFPIA - European Federation of Pharmaceutical Industries and Associations
    Clara Cuervo
    Clara Cuervo, Head of AI and Digital Transformation Cell Therapy Clinical Operations Global - AstraZeneca
    Domitille Halie
    Domitille Halie, Head of Scientific Project Management - WhiteLab Genomics
    Marc Guell
    Marc Guell, Cofounder & Scientific Head - Integra Therapeutics
    Vasiliki Kalodimou
    Vasiliki Kalodimou, Assistant Professor - European University Cyprus
11:15
  1. Break
    Exhibition Hall
    30 mins
    • Networking Break
     
Loading
Search Filters
  • Speakers
  • Audience
  • Topic
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
15:00
  1. Spotlight: A new lentiviral vector for in vivo CAR-T with high specificity and efficacy for multi-immune cell targeting
    Theatre 1 (Zafir)
    15 mins
    • Cell & Gene Therapy Clinical Pathways
     
    Stefanos Theoharis
    Stefanos Theoharis, CEO - OneChain Immunotherapeutics
15:05
  1. Presentation: A novel manufacturing platform for making any cell therapy a tumour targeted cell therapy.
    Workshop Room (Rossini 1&2)
    10 mins
    • Innovation Zone
     
    David Coe
    David Coe, CEO - CoED Biosciences
15:15
  1. Panel: The in vivo inflection: From breakthrough to clinical momentum, how far and how fast can this wave go?
    Theatre 1 (Zafir)
    45 mins
    • Cell & Gene Therapy Clinical Pathways
    The inflection is measurable: What recent in vivo clinical readouts are showing about delivery efficiency, expression control and safety—and where performance is becoming reproducible rather than exce ...
    Andrew Frazer
    Andrew Frazer, Associate Director, Scientific Solutions - Rose BioSolutions
    Margot Pont
    Margot Pont, VP Translational Development - Integra Therapeutics
    Maria Eugenia Alonso Ferrero
    Maria Eugenia Alonso Ferrero, Immunogenecity Science Director - Alexion Pharmaceuticals
    Stefanos Theoharis
    Stefanos Theoharis, CEO - OneChain Immunotherapeutics
  2. Panel: From scaled to standard of care: commercialising CGTs across Europe’s fragmented health systems
    Theatre 2 (Rubi)
    45 mins
    • Operational & Commercial Performance
     
    Angela Borghouts de Ruijter
    Angela Borghouts de Ruijter, Associate Director Market Access - Gilead
    Esteve Trias
    Esteve Trias, ATMP Expert
    Francis Pang
    Francis Pang, Senior Vice President, Global Market Access and International Geographic Expansion - Orchard Therapeutics
    Tamara Loos
    Tamara Loos, Consultant - ENIMAXE
16:00
  1. Break
    Exhibition Hall
    30 mins
    • Networking Break
     
16:30
  1. Roundtable: From Investment to Impact: The social return on novel therapies
    60 mins
    • Roundtable
    Angela Borghouts de Ruijter
    Angela Borghouts de Ruijter, Associate Director Market Access - Gilead
  2. Roundtable: From bench to build: How academic scientists turn ideas into fundable biotechs
    60 mins
    • Roundtable
    Laura Koivusalo
    Laura Koivusalo, CEO - StemSight
  3. Roundtable: Choosing Your Modality Early and Living With It: How platform, delivery and indication choices shape timelines, capital needs and exit options
    60 mins
    • Roundtable
    Carolina Pola
    Carolina Pola, CEO - STAb Therapeutics
  4. Roundtable: Creating visibility across the patient cell journey: Building customer engagement into CAR-T operations
    60 mins
    • Roundtable
    Danny Evans
    Danny Evans, Customer experience & commercial operations expert, Advanced Therapies - Lima Lime Consulting
  5. Roundtable: Cracking the EU Code: Turning regulatory & supply complexities into a smooth process
    60 mins
    • Roundtable
    Cristina Salado
    Cristina Salado, Assistant Professor - Universitat Pompeu Fabra
  6. Roundtable: Data that unlocks capital: What investors actually want to see at seed and Series A and what doesn’t move the needle
    60 mins
    • Roundtable
    Raphael Ognar
    Raphael Ognar, Co-founder - NKILT Therapeutics
  7. Roundtable: From great science to great business: Translating innovation into investment, commercialization and exit
    60 mins
    • Roundtable
    Mayra Battilani Becegato
    Mayra Battilani Becegato, Founder - AltrionBio
  8. Roundtable: Managing immunogenicity risk across the next generation of advanced therapies
    60 mins
    • Roundtable
    Maria Eugenia Alonso Ferrero
    Maria Eugenia Alonso Ferrero, Immunogenecity Science Director - Alexion Pharmaceuticals
  9. Roundtable: Moving biology across borders: Import/export, customs, chain-of-custody and compliance - What still trips teams up in 2026
    60 mins
    • Roundtable
    Lynette James
    Lynette James, VP Supply Chain & External Manufacturing - Quell Therapeutics
  10. Roundtable: Where impact meets returns: Rethinking how biotechs are built and funded
    60 mins
    • Roundtable
    Gonzalo Fernandez-Miranda
    Gonzalo Fernandez-Miranda, Co-founder & CEO - CureAge Therapeutics
17:30
  1. Drinks Reception
    Exhibition Hall
    105 mins
    • Networking Break
     
18:00
  1. CellBri Barcelona Demo Lab Tour
    InterContinental Hotel
    120 mins
    • Operational & Commercial Performance
    CellBri will be hosting an exclusive visit to our new demonstration facility at Cosymbio in Barcelona. Join us for an exclusive tour of our new demonstration lab at Cosymbio in Barcelona on September ...
09:00
  1. Innovation Exchange
    Theatre 1 (Zafir)
    90 mins
    • Plenary
    Join us for an exciting session where innovative biotech start-ups pitch their groundbreaking ideas and solutions. Watch as they present to a panel of expert investors, who will provide real-time feed ...
    Gadareth Higgs
    Gadareth Higgs, Partner - Advantary Capital Partners
    Malgorzata Rogalska
    Malgorzata Rogalska, Analyst - Ysios Capital
    Matt Symes
    Matt Symes, Investor - Delin Ventures
    Rahul Khetan
    Rahul Khetan, Venture Associate - UCB Ventures
10:30
  1. Panel: Designing CGTs in the age of agentic AI: How AI is transforming discovery and development
    Theatre 1 (Zafir)
    45 mins
    • Plenary
    From optional to inevitable: Where agentic and analytical AI are already changing discovery and early CGT development and what must be true for AI to become a trusted, default tool rather than a pilot ...
    Aneta Tyszkiewicz
    Aneta Tyszkiewicz, Director Data Digital - EFPIA - European Federation of Pharmaceutical Industries and Associations
    Clara Cuervo
    Clara Cuervo, Head of AI and Digital Transformation Cell Therapy Clinical Operations Global - AstraZeneca
    Domitille Halie
    Domitille Halie, Head of Scientific Project Management - WhiteLab Genomics
    Marc Guell
    Marc Guell, Cofounder & Scientific Head - Integra Therapeutics
    Vasiliki Kalodimou
    Vasiliki Kalodimou, Assistant Professor - European University Cyprus
11:15
  1. Break
    Exhibition Hall
    30 mins
    • Networking Break
     
Search